Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control

Overview

In this study, the task was to evaluate the effectiveness of prescribing small doses of quetiapine (25-75 mg) for bipolar patients in remission in order to relieve symptoms of impulsivity.

The purpose of this study is to study the efficacy and safety of the administration of Quetiapine ® in small doses (25-75 mg / day) to patients diagnosed with bipolar disorder who are in an euthymic state with signs of impaired impulse control. The method of administration, dosage regimen and duration of taking quetiapine in this study: 1-3 tablets from one to 3 times a day, regardless of food intake for 28 days. Each patient included in the program will be given a package with the drug for 14 days of admission. In the first 14 days of administration, dose adjustment is possible in the range from 25 to 75 mg, depending on individual tolerability. The decision on correction is made by the doctor based on a phone call to the patient after the first week of taking the drug at a dose of 25 mg. Correction is also possible at a later or earlier date during the first two weeks of therapy. At visit 2, the patient will have to provide the doctor with a package of the drug as part of the compliance assessment. At visit 2, the doctor should give the patient packages with the drug for 28 days of admission and ask them to bring packages to assess compliance and account for the drug for visit 3. Screening (Visit 1 / Day 0) The inclusion of the subject in the program will be carried out on the basis of an assessment of demographic, clinical characteristics, anamnesis data. Prior to the start of the examination, the subject must be provided with oral information about the nature of the study, an informed consent form for signing. The following procedures will be performed during the screening: * Collection of demographic data; * Medical history (previous and concomitant diseases, surgical interventions, allergic history, gynecological history); * Confirmation of the diagnosis * Evaluation of inclusion/non-inclusion criteria; \-- Registration of the drug (or other) therapy that the study participant receives; * The presence of bad habits; * Rating on the YMRS scale; * Assessment on the MADRS scale; * Assessment on the Barratt impulsivity scale; * Score on the Go-no-go task * Score on the Ballon Analog Risk Task (BART) * Delivery of the drug * Functional magnetic resonance imaging (fMRI) (optional) Visit 2 / Day 14±3 The following procedures will be carried out on Visit 2: * Registration of the drug (or other) therapy that the study participant receives; * Assessment of the subject's compliance; * Correction of the dose of the drug\*; * Registration of adverse reactions / adverse events; * Assessment on the Barratt impulsivity scale; * Score on the Go-no-go task * Score on the Ballon Analog Risk Task (BART) * Delivery of the drug * fMRI (optional) Visit 3 / Day 42±3 Registration of the drug (or other) therapy that the study participant receives; * Assessment of the subject's compliance; * Registration of adverse reactions / adverse events; * Assessment on the Barratt impulsivity scale; * Score on the Go-no-go task * Score on the Ballon Analog Risk Task (BART) * fMRI (optional) Concomitant therapy Within the framework of this study, patients can receive any pharmacotherapy therapy, with the exception of quetiapine in higher doses than prescribed by the protocol. At each visit, the doctor should interview the patient about any medications used by the patient during participation in the study. Information about the patient's intake of concomitant medications is entered by the doctor in the IRC. Functional magnetic resonance imaging (fMRI) As part of this study, an additional fMRI procedure will be performed for a part of patients (10 people) to assess the functional activity of the brain when performing the Go-no-GO test. Total duration of the study The expected duration of the subjects' participation in the study corresponds to the expected duration of taking the drug and for each participant will be 42 ± 3 days. The inclusion of patients in the study will continue until their total number reaches 30 people.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts